- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03033836
Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women (TRANSViiV)
Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women
Prospective, open, single-arm trial of dolutegravir-tenofovir and emtricitabine or lamivudine (DTG-TDF-FTC or 3TC) in antiretroviral (ART) naïve HIV transgender women (TGW).
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC or 3TC
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
Studie Overzicht
Gedetailleerde beschrijving
The primary objective of this pilot study is to determine the retention in care of TGW treated with DTG-TDF-FTC.
The primary objective will be assessed by the proportion of individuals that provide information on ART use and virological outcomes at the end of the study:
- Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up.
- Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up.
Secondary objectives:
- To evaluate the efficacy of the antiretroviral regimen at week 48 ;
- To describe the safety and tolerability of this regimen;
- To evaluate adherence across 48 weeks;
- To determine the patient satisfaction with this regimen;
- To identify individual, social and contextual factors associated with adherence and retention.
The secondary objectives will be evaluated using the following endpoints:
- Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
- Frequency, type and severity of adverse events and laboratory abnormalities;
- Pill count, analogue visual scale for adherence in each visit;
- Changes in the scores of stigma and discrimination scales , quality of life, social support and anxiety and depression (BERGER, WBI,DUKE,CES-D,STAI) at bsl, 4,24, and 48 weeks e;.Changes in the score scales of sexual behaviors, use of drug /alcohol at bsl and at each visit .
f. Through association of baseline individual, social and contextual characteristics with percentage of adherence and retention at 48 weeks.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
Buenos Aires
-
Ciudad de Buenos Aires, Buenos Aires, Argentinië, C1202ABB
- Fundación Huésped
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- HIV-1 positive serology by at least two different serological tests (rapid test, ELISA, Western Blot) or a viral load higher than 3,000 copies/mL.
- 18 years and older.
- Self-identified as TGW
- ART naïve.
- Written informed consent provided.
Exclusion Criteria:
- Genotypic resistance to TDF and/or FTC as per IAS-USA resistance panel 2013.
- Alcohol or drug use that might affect adherence.
- Concomitant use of lipid-lowering drugs, interferon, interleukin-2, cytotoxic chemotherapy, dofetilide (or pilsicainide) or immunosuppressors, antacids drugs containing Ca++ and or Mg++ at study entry.
- Opportunistic infection (CDC "C" category) or other disease and/or clinical conditions that, in the investigator's opinion, would compromise the patient's safety or outcome of the study; including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia.
- Treatment with any of the following agents within 28 days of screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening or exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of the investigational product.
- Contraindication to any of the study drugs (history of renal diseases, lab abnormalities grade 4 or any other clinical condition prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements).
- Anticipated need for Hepatitis C virus (HCV) therapy during the study.
- Creatinine clearance of <50 mL/min via Cockroft-Gault method.
- Subjects with moderate to severe hepatic impairment (Class B or greater) as determined by Child-Pugh classification.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: single arm
ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
|
Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of transgender women retained in care at week 48
Tijdsspanne: 48 weeks
|
Proportion of enrolled and dosed individuals that complete protocol defined visits during 48 weeks of follow up. Retention under care: Proportion of enrolled and dosed individuals that provide clinical information up to 48 weeks of follow up. Retention on treatment: Proportion of enrolled and dosed individuals that receive study drugs up to 48 weeks of follow up. |
48 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of individuals with HIV RNA undetectable at week 48
Tijdsspanne: 48 weeks
|
Proportion of patients with HIV-1 RNA levels less than 50 copies/mL at week 48 weeks of treatment by the IIT-exposed snapshot FDA algorithm;
|
48 weeks
|
|
Percentage of Participants Experiencing Any Treatment-Emergent Laboratory Abnormality
Tijdsspanne: From baseline to week 48
|
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline.
The most severe graded abnormality from all tests was counted for each participant.
|
From baseline to week 48
|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Tijdsspanne: From baseline to week 48
|
Adverse events (AEs) occurring during treatment and for 30 days following the last dose of study drug were summarized across the participant population.
A participant was counted once if they had a qualifying event.
|
From baseline to week 48
|
|
Adherence using ACTG form
Tijdsspanne: From baseline to week 48
|
ACTG self report adherence form will be used for baseline and follow up visits
|
From baseline to week 48
|
|
Adherence using analogue visual scale
Tijdsspanne: From week 4 to week 48
|
Analogue visual scale (0-10) will be used at each follow up visit
|
From week 4 to week 48
|
|
Adherence by pill count
Tijdsspanne: From week 4 to week 48
|
Pill count of dispensed drugs
|
From week 4 to week 48
|
|
Quality of life by QoL Socre and Well being index
Tijdsspanne: From baseline to week 48
|
Changes in the scores of quality of life, will be done through Well-being Index questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
|
Patient´s satisfaction with this regimen
Tijdsspanne: From baseline to week 48
|
Changes in the scores of social support,will be done through Duke UNC questionnaire, this instrument will be administered to patients at baseline, week 4, 24 and week 48 .
|
From baseline to week 48
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Omar Sued, MD, PhMD, Fundación Huésped
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- RNA-virusinfecties
- Virusziekten
- Infecties
- Door bloed overgedragen infecties
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- Lentivirus-infecties
- Retroviridae-infecties
- Immunologische deficiëntie syndromen
- Ziekten van het immuunsysteem
- HIV-infecties
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Reverse Transcriptase-remmers
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Anti-hiv-middelen
- Antiretrovirale middelen
- Hiv-integraseremmers
- Integrase-remmers
- Emtricitabine, tenofovirdisoproxilfumaraat Geneesmiddelcombinatie
- Dolutegravir
Andere studie-ID-nummers
- FH-17
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .